Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Ella Ariza‐Heredia(The University of Texas MD Anderson Cancer Center), Ying Jiang(The University of Texas MD Anderson Cancer Center), Kathleen M Mulane(University of Illinois Chicago), Sherif B. Mossad(Cleveland Clinic), Parameswaran Hari(Medical College of Wisconsin), Sanjeet Dadwal(City Of Hope National Medical Center), Dimpy P. Shah(The University of Texas MD Anderson Cancer Center), Ted Blanchard(Evotec (United States)), Deepali Kumar(University Health Network), Scott D. Rowley(Johns Hopkins Hospital), Per Ljungman(Leiden University Medical Center), Rajneesh Nath(The University of Texas MD Anderson Cancer Center), Drew J. Winston(University of California, Los Angeles), Karl S. Peggs(University College Hospital), Pranatharthi Chandrasekar(Wayne State University), Lynn El Haddad(The University of Texas MD Anderson Cancer Center), Robin K. Avery(Johns Hopkins University)
Cited by 109
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k